OKYO Pharma Limited Announces Share Purchase by Executive Chairman
London and New York, Aug. 23, 2024
OKYO Pharma Limited (NASDAQ: OKYO) – A Clinical-Stage Biopharmaceutical Company
OKYO Pharma Limited, a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED) and anterior ocular segment diseases including neuropathic corneal pain (NCP), announced today that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.05 per share. This brings the total shareholding of Mr Cerrone to 9,721,570 shares which is 28.73% of issued share capital.
The purchase of shares by the Executive Chairman demonstrates confidence in the company’s potential for growth and success in the biopharmaceutical industry. With a focus on developing therapies for ocular conditions that currently lack FDA-approved treatments, OKYO Pharma Limited is poised to make a significant impact on the medical field.
By investing in research and development, OKYO Pharma Limited aims to address the unmet needs of patients suffering from inflammatory dry eye disease and neuropathic corneal pain. These conditions can significantly impact the quality of life for those affected, and the innovative therapies being developed by the company have the potential to improve outcomes and provide much-needed relief.
As the company continues to make strides in the field of ocular therapeutics, investors and stakeholders can look forward to the potential for growth and expansion. With a strong leadership team and a commitment to advancing novel treatment options, OKYO Pharma Limited is well-positioned for success in the competitive biopharmaceutical market.
Impact on Individuals:
For individuals, the developments at OKYO Pharma Limited could mean access to new treatment options for conditions such as inflammatory dry eye disease and neuropathic corneal pain. Patients suffering from these conditions may benefit from innovative therapies that improve their quality of life and provide relief from symptoms.
Global Impact:
On a global scale, OKYO Pharma Limited’s focus on developing therapies for ocular conditions could have far-reaching implications for public health. By addressing unmet medical needs and advancing research in the field of ocular therapeutics, the company has the potential to improve outcomes for patients worldwide and contribute to the advancement of healthcare.
Conclusion:
The purchase of shares by the Executive Chairman signals a vote of confidence in OKYO Pharma Limited’s mission to develop innovative ocular therapies. As the company continues to make progress in the biopharmaceutical industry, individuals and the global community stand to benefit from the potential improvements in treatment options and healthcare outcomes.
